Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Retrospective German Society for Amyloid Diseases study of teclistamab in relapsed/refractory AL amyloidosis finds ≥VGPR in 95% 3 mos, cardiac and renal ≥PR 6 mos were 65% & 78%, lower infxn and death rate w/ IV Ig.”
Title: Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases
Authors: Alexander Carpinteiro, Christoph Kimmich, Despina Trajanova, Ute Hegenbart, Timon Hansen, Udo Holtick, Vera von Landenberg-Roberg, Stephan Rainer Bohl, Raphael Teipel, Ivana von Metzler, Monika Engelhardt, Evgenii Shumilov, Maximilian Steinhardt, Hans Christian Reinhardt, Sara Oubari, Stefan Schönland
You can read the Full Article on HemaSphere.
You can find other articles featuring Robert Orlowski on OncoDaily.
